Drug Profile
Graphene nanoribbons - Theragnostic Technologies
Alternative Names: O-GNR-PEG-DSPELatest Information Update: 11 Sep 2023
Price :
$50
*
At a glance
- Originator Theragnostic Technologies
- Class Antineoplastics; Antivirals; Imaging agents
- Mechanism of Action Diagnostic imaging enhancers; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer; Cervical cancer; Head and neck cancer; Herpesvirus infections
Most Recent Events
- 11 Sep 2023 Discontinued - Preclinical for Breast cancer (Metastatic disease) in USA (Parenteral) (Theragnostic Technologies Website, September 2023)
- 11 Sep 2023 Discontinued - Preclinical for Cervical cancer in USA (Parenteral) (Theragnostic Technologies Website, September 2023)
- 11 Sep 2023 Discontinued - Preclinical for Head and neck cancer in USA (Parenteral) (Theragnostic Technologies Website, September 2023)